San Antonio Breast Cancer Symposium

Transcription

1 Tuesday, December 8, EDUCATION SESSIONS 12:35 p.m. Careers in Translational Research Geoffrey Shapiro, MD, PhD Director, Early Drug Development Center Clinical Director, Center for DNA Damage and Repair Senior Physician Wednesday, December 9, December 8-12, EDUCATION SESSIONS 8:15 a.m. Critical Decision Making in Radiation Therapy for in Jay R. Harris, MD Chair of the Department of Radiation Oncology at Dana- Farber/Brigham and Women's Cancer Center (DF/BWCC) 2:15 p.m. Hacking the Hormone Code in ER+ Myles A. Brown, MD Physician Director, Center for Functional Cancer Epigenetics MINI-SYMPOSIUM 1 2:15 p.m. Beyond CDK 4/6: Targeting additional cell cycle and transcriptional CDKs in breast cancer Geoffrey Shapiro, MD, PhD Director, Early Drug Development Center Clinical Director, Center for DNA Damage and Repair Senior Physician POSTER SESSION 1 The incidence of and survival after breast cancer recurrence P Michael Hassett, MD Page 1

2 Wednesday, December 9, POSTER SESSION 1 (continued) Predisposing germline mutations in a clinic based breast cancer (BC) population P Judy Garber, MD, MPH December 8-12, Factors associated with delays in chemotherapy initiation among patients with breast cancer P Craig Bunnell, MD, MPH, MBA ONGOING CLINICAL TRIALS SESSION 1 A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mtnbc) OT Eric Winer, MD A phase 2 study of abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer OT Sara Tolaney MD, MPH PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer OT Erica Mayer MD, MPH Page 2

3 Thursday, December 10, POSTER SESSION 2 7:30-9:00 a.m. Implementation of a breast/reconstructive surgery coordinator to reduce preoperative delays for patients undergoing mastectomy with immediate reconstruction P Mehra Golshan, MD, FACS December 8-12, Immune activation signatures identify a subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant chemotherapy P Daniel Stover, MD Exploring bazedoxifene and palbociclib as potential therapeutic strategies for overcoming ESR1-mediated endocrine resistance P Rinath M. Jeselsohn, MD POSTER DISCUSSION 3 5:00 p.m. PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 Nikhil Wagle, MD Page 3

4 Thursday, December 10, ONGOING CLINICAL TRIALS SESSION 2 Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER+/AR+ breast cancer (BC) in postmenopausal (PM) women OT December 8-12, The metastatic breast cancer project: A national direct-topatient research initiative to accelerate genomics research OT Nikhil Wagle, MD Friday, December 11, POSTER SESSION 4 7:30-9:00 a.m. MRI changes in breast skin following preoperative therapy for inflammatory breast cancer (IBC) P Genetic predictors of chemotherapy-related amenorrhea P Ann Partridge MD, MPH Employment trends in young women following a breast cancer diagnosis P Ann Partridge MD, MPH. Page 4

5 Friday, December 11, POSTER SESSION 4 (Continued) GENERAL SESSION 5 10:30 a.m. Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer P Sara Tolaney, MD, MPH December 8-12, POSTER SESSION 5 Trastuzumab emtansine improves overall survival versus treatment of physician s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study Ian Krop, MD, PhD Incidence and prognostic importance of hyponatremia in a cohort of patients with breast cancer P Jorge Castillo, MD Medical Oncology Survival benefit needed to undergo chemotherapy: Patients and physicians preferences P Ann Partridge, MD, MPH What goes through your mind when you think about your medication? Thoughts about endocrine medication and treatment adherence P Ann Partridge, MD, MPH Page 5 POSTER DISCUSSION 6 Translational Genomics - Ballroom B Nikhil Wagle, MD, Co-Discussant

6 Friday, December 11, POSTER DISCUSSION 6 Translational Genomics - Ballroom B Nikhil Wagle, MD, Co-Discussant December 8-12, POSTER DISCUSSION 7 Clinical Applications of Hereditary Multigene Panels - Ballroom A Judy E. Garber, MD, MPH, Co-Discussant Saturday, December 12, POSTER SESSION 6 7:30-9:00 a.m. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer P Tumor profiling of inflammatory breast cancer: Advancing the tools needed for precision medicine P :00 a.m. The Year in Review: Update on Basic Science Discoveries Myles A. Brown, MD Director, Center for Functional Cancer Epigenetics Page 6